Bild 1 von 1
Bild 1 von 1
Präklinische Sicherheitsbewertung von Biopharmazeutika: Ein wissenschaftlich fundierter Ansatz...-
US $26,72
Ca.EUR 24,00
oder Preisvorschlag
Artikelzustand:
Sehr gut
Buch, das nicht neu aussieht und gelesen wurde, sich aber in einem hervorragenden Zustand befindet. Der Einband weist keine offensichtlichen Beschädigungen auf. Bei gebundenen Büchern ist der Schutzumschlag vorhanden (sofern zutreffend). Alle Seiten sind vollständig vorhanden, es gibt keine zerknitterten oder eingerissenen Seiten und im Text oder im Randbereich wurden keine Unterstreichungen, Markierungen oder Notizen vorgenommen. Der Inneneinband kann minimale Gebrauchsspuren aufweisen. Minimale Gebrauchsspuren. Genauere Einzelheiten sowie eine Beschreibung eventueller Mängel entnehmen Sie bitte dem Angebot des Verkäufers.
- Sofort-KaufenPräklinische Sicherheitsbewertung von Biopharmazeutika: Ein wissenschaftlich fundierter Ansatz...
Versand:
Kostenlos USPS Media MailTM.
Standort: San Diego, California, USA
Lieferung:
Lieferung zwischen Mo, 30. Sep und Fr, 4. Okt nach 43230 bei heutigem Zahlungseingang
Rücknahme:
14 Tage Rückgabe. Kostenloser Rückversand.
Zahlungen:
Sicher einkaufen
Der Verkäufer ist für dieses Angebot verantwortlich.
eBay-Artikelnr.:326106582010
Artikelmerkmale
- Artikelzustand
- Release Year
- 2008
- Book Title
- Preclinical Safety Evaluation of Biopharmaceuticals: A Science...
- ISBN
- 9780470108840
- Subject Area
- Science, Medical
- Publication Name
- Preclinical Safety Evaluation of Biopharmaceuticals : A Science-Based Approach to Facilitating Clinical Trials
- Publisher
- Wiley & Sons, Incorporated, John
- Item Length
- 9.5 in
- Subject
- Pharmacology, Life Sciences / Biology
- Publication Year
- 2008
- Type
- Textbook
- Format
- Hardcover
- Language
- English
- Item Height
- 2.4 in
- Item Weight
- 58.2 Oz
- Item Width
- 6.5 in
- Number of Pages
- 1064 Pages
Über dieses Produkt
Product Identifiers
Publisher
Wiley & Sons, Incorporated, John
ISBN-10
0470108843
ISBN-13
9780470108840
eBay Product ID (ePID)
65705855
Product Key Features
Number of Pages
1064 Pages
Publication Name
Preclinical Safety Evaluation of Biopharmaceuticals : A Science-Based Approach to Facilitating Clinical Trials
Language
English
Subject
Pharmacology, Life Sciences / Biology
Publication Year
2008
Type
Textbook
Subject Area
Science, Medical
Format
Hardcover
Dimensions
Item Height
2.4 in
Item Weight
58.2 Oz
Item Length
9.5 in
Item Width
6.5 in
Additional Product Features
Intended Audience
Scholarly & Professional
LCCN
2007-050275
Dewey Edition
22
Reviews
"For scientists who are intimately involved with biopharmaceutical development, a copy of the book for their personal library is mandatory. Those who may not be intimately involved in biopharmaceutical development but may have an interest in the progress of a biotherapeutic agent will find this book a valuable resource and a reminder for the need of evaluating the safety of biotherapeutics by looking at each biopharmaceutical on a case-by-case approach." ( International Journal of Toxicology , March/April 2009)
Illustrated
Yes
Dewey Decimal
615.19
Synopsis
The goal is to provide a comprehensive reference book for the preclinicaldiscovery and development scientist whose responsibilities span target identification, lead candidate selection, pharmacokinetics, pharmacology, and toxicology, and for regulatory scientists whose responsibilities include the evaluation of novel therapies.|9780470108840|, The goal is to provide a comprehensive reference book for the preclinicaldiscovery and development scientist whose responsibilities span target identification, lead candidate selection, pharmacokinetics, pharmacology, and toxicology, and for regulatory scientists whose responsibilities include the evaluation of novel therapies. --From the Afterword by Anthony D. Dayan Proper preclinical safety evaluation can improve the predictive value, lessen the time and cost of launching new biopharmaceuticals, and speed potentially lifesaving drugs to market. This guide covers topics ranging from lead candidate selection to establishing proof of concept and toxicity testing to the selection of the first human doses. With chapters contributed by experts in their specific areas, Preclinical Safety Evaluation of Biopharmaceuticals: A Science-Based Approach to Facilitating Clinical Trials Includes an overview of biopharmaceuticals with information on regulation and methods of production Discusses the principles of ICH S6 and their implementation in the U.S., Europe, and Japan Covers current practices in preclinical development and includes a comparison of safety assessments for small molecules with those for biopharmaceuticals Addresses all aspects of the preclinical evaluation process, including: the selection of relevant species; safety/toxicity endpoints; specific considerations based upon class; and practical considerations in the design, implementation, and analysis of biopharmaceuticals Covers transitioning from preclinical development to clinical trials This is a hands-on, straightforward reference for professionals involved in preclinical drug development, including scientists, toxicologists, project managers, consultants, and regulatory personnel., "The goal is to provide a comprehensive reference book for the preclinicaldiscovery and development scientist whose responsibilities span target identification, lead candidate selection, pharmacokinetics, pharmacology, and toxicology, and for regulatory scientists whose responsibilities include the evaluation of novel therapies." --From the Afterword by Anthony D. Dayan Proper preclinical safety evaluation can improve the predictive value, lessen the time and cost of launching new biopharmaceuticals, and speed potentially lifesaving drugs to market. This guide covers topics ranging from lead candidate selection to establishing proof of concept and toxicity testing to the selection of the first human doses. With chapters contributed by experts in their specific areas, Preclinical Safety Evaluation of Biopharmaceuticals: A Science-Based Approach to Facilitating Clinical Trials Includes an overview of biopharmaceuticals with information on regulation and methods of production Discusses the principles of ICH S6 and their implementation in the U.S., Europe, and Japan Covers current practices in preclinical development and includes a comparison of safety assessments for small molecules with those for biopharmaceuticals Addresses all aspects of the preclinical evaluation process, including: the selection of relevant species; safety/toxicity endpoints; specific considerations based upon class; and practical considerations in the design, implementation, and analysis of biopharmaceuticals Covers transitioning from preclinical development to clinical trials This is a hands-on, straightforward reference for professionals involved in preclinical drug development, including scientists, toxicologists, project managers, consultants, and regulatory personnel., "The goal is to provide a comprehensive reference book for the preclinicaldiscovery and development scientist whose responsibilities span target identification, lead candidate selection, pharmacokinetics, pharmacology, and toxicology, and for regulatory scientists whose responsibilities include the evaluation of novel therapies." --From the Afterword by Anthony D. Dayan Proper preclinical safety evaluation can improve the predictive value, lessen the time and cost of launching new biopharmaceuticals, and speed potentially lifesaving drugs to market. This guide covers topics ranging from lead candidate selection to establishing proof of concept and toxicity testing to the selection of the first human doses. With chapters contributed by experts in their specific areas, Preclinical Safety Evaluation of Biopharmaceuticals: A Science-Based Approach to Facilitating Clinical Trials : Includes an overview of biopharmaceuticals with information on regulation and methods of production Discusses the principles of ICH S6 and their implementation in the U.S., Europe, and Japan Covers current practices in preclinical development and includes a comparison of safety assessments for small molecules with those for biopharmaceuticals Addresses all aspects of the preclinical evaluation process, including: the selection of relevant species; safety/toxicity endpoints; specific considerations based upon class; and practical considerations in the design, implementation, and analysis of biopharmaceuticals Covers transitioning from preclinical development to clinical trials This is a hands-on, straightforward reference for professionals involved in preclinical drug development, including scientists, toxicologists, project managers, consultants, and regulatory personnel., "The goal is to provide a comprehensive reference book for the preclinicaldiscovery and development scientist whose responsibilities span target identification, lead candidate selection, pharmacokinetics, pharmacology, and toxicology, and for regulatory scientists whose responsibilities include the evaluation of novel therapies." From the Afterword by Anthony D. Dayan Proper preclinical safety evaluation can improve the predictive value, lessen the time and cost of launching new biopharmaceuticals, and speed potentially lifesaving drugs to market. This guide covers topics ranging from lead candidate selection to establishing proof of concept and toxicity testing to the selection of the first human doses. With chapters contributed by experts in their specific areas, Preclinical Safety Evaluation of Biopharmaceuticals: A Science-Based Approach to Facilitating Clinical Trials: Includes an overview of biopharmaceuticals with information on regulation and methods of production Discusses the principles of ICH S6 and their implementation in the U.S., Europe, and Japan Covers current practices in preclinical development and includes a comparison of safety assessments for small molecules with those for biopharmaceuticals Addresses all aspects of the preclinical evaluation process, including: the selection of relevant species; safety/toxicity endpoints; specific considerations based upon class; and practical considerations in the design, implementation, and analysis of biopharmaceuticals Covers transitioning from preclinical development to clinical trials This is a hands-on, straightforward reference for professionals involved in preclinical drug development, including scientists, toxicologists, project managers, consultants, and regulatory personnel.
LC Classification Number
RS380.P74 2008
Artikelbeschreibung des Verkäufers
Angemeldet als gewerblicher Verkäufer
Verkäuferbewertungen (5.001)
- r***r (24)- Bewertung vom Käufer.Letzte 6 MonateBestätigter Kaufgreat communication, it arrived earlier than estimated, and good packaging. item came in good condition and was true to the description and sold for a good price. overall great seller A+++Holy Bible Placed by The Gideons In Memory Blue Cover In Great Condition (Nr. 326088641776)
- h***f (72)- Bewertung vom Käufer.Letzte 6 MonateBestätigter KaufReally fast shipping, i ordered this maybe 3 days ago and was surprised to find it in my mailbox today. Excellent condition. As described. Well packaged and no damage to book during shipping.The Elementals (Nr. 326140764726)
- o***5 (410)- Bewertung vom Käufer.Letzte 6 MonateBestätigter KaufItem purchased was exactly as described and shown in pics, price was fair, shipping was fast, communication was excellent! I highly recommend this Seller! AAA+++America's Secret Army: The Untold Story of the Counter Intelligence Corps (Nr. 326156874529)
Produktbewertungen & Rezensionen
Noch mehr entdecken:
- Science-Fiction-Belletristik Romane,
- Bücher über Literatur Science-Fiction-Belletristik,
- Science-Fiction-Belletristik-Bücher auf Deutsch,
- Science-Fiction-Belletristik-Jugendliche Romane,
- Ray-Bradbury-Science-Fiction - Belletristik-Bücher,
- Isaac-Asimov-Science-Fiction - Belletristik-Bücher,
- Belletristik im Taschenbuch-Format mit Romane Science-Fiction,
- H.P. - Lovecraft-Science-Fiction-Belletristik - Bücher,
- Star Trek Science-Fiction-Bücher mit Belletristik-Genre,
- Michael-Crichton-Science-Fiction - Belletristik-Bücher